Investment Analysts’ Recent Ratings Updates for Ionis Pharmaceuticals (IONS)

Several brokerages have updated their recommendations and price targets on shares of Ionis Pharmaceuticals (NASDAQ: IONS) in the last few weeks:

• 3/3/2026 – Ionis Pharmaceuticals had its price target raised by Leerink Partners from $102.00 to $104.00. They now have an “outperform” rating on the stock.
• 2/28/2026 – Ionis Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/27/2026 – Ionis Pharmaceuticals had its price target raised by Piper Sandler from $87.00 to $100.00. They now have an “overweight” rating on the stock.
• 2/26/2026 – Ionis Pharmaceuticals had its price target raised by Stifel Nicolaus from $73.00 to $77.00. They now have a “hold” rating on the stock.
• 2/25/2026 – Ionis Pharmaceuticals was given a new $95.00 price target by Morgan Stanley. They now have an “overweight” rating on the stock.
• 2/25/2026 – Ionis Pharmaceuticals had its price target raised by Needham & Company LLC from $90.00 to $103.00. They now have a “buy” rating on the stock.
• 2/25/2026 – Ionis Pharmaceuticals had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 2/6/2026 – Ionis Pharmaceuticals had its price target raised by Piper Sandler from $77.00 to $87.00. They now have an “overweight” rating on the stock.
• 1/28/2026 – Ionis Pharmaceuticals is now covered by Barclays PLC. They set an “overweight” rating and a $95.00 price target on the stock.
• 1/22/2026 – Ionis Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/5/2026 – Ionis Pharmaceuticals had its price target raised by Wells Fargo & Company from $82.00 to $100.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, Director Allene M. Diaz sold 54,878 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $79.35, for a total transaction of $4,354,569.30. Following the transaction, the director directly owned 3,811 shares in the company, valued at $302,402.85. This represents a 93.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP C Frank Bennett sold 85,089 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $79.23, for a total transaction of $6,741,601.47. Following the transaction, the executive vice president directly owned 80,554 shares in the company, valued at $6,382,293.42. This trade represents a 51.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 596,652 shares of company stock valued at $48,059,821 over the last quarter. 2.60% of the stock is owned by company insiders.

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.